Mackay Shields LLC Fate Therapeutics Inc Transaction History

Mackay Shields LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$67.25 - $92.52 $1.59 Million - $2.18 Million	-23,600 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$72.16 - $117.4 $1.08 Million - $1.76 Million	-15,000 Reduced 38.86%	23,600 $1.95 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $426,608 - $1.13 Million	-11,200 Reduced 22.49%	38,600 $3.51 Million
Q3 2020 Nov 04, 2020	SELL	$30.41 - $40.5 $161,173 - $214,650	-5,300 Reduced 9.62%	49,800 $1.99 Million
Q2 2020 Jul 31, 2020	BUY	$20.21 - $35.23 $650,762 - $1.13 Million	32,200 Added 140.61%	55,100 $1.89 Million
Q1 2020 May 08, 2020	BUY	$17.28 - $31.88 $395,712 - $730,052	22,900 New	22,900 $509,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Mackay Shields LLC, based on Form 13F filings with the SEC.

Stay updated on Mackay Shields LLC with notifications on news.